Treatment of Osteoporosis With Anabolic Agents and the Risk of Primary Bone Cancers: A Study of 44,728 Patients Treated With Teriparatide and Abaloparatide

医学 合成代谢 特立帕肽 入射(几何) 恶性肿瘤 骨质疏松症 队列 内科学 风险因素 外科 合成代谢剂 肿瘤科 骨矿物 物理 光学
作者
Christopher L. McDonald,Keir Johnson,Daniel Alsoof,Janine Molino,Mariah Balmaceno-Criss,Alan H. Daniels
出处
期刊: [American Academy of Orthopaedic Surgeons]
卷期号:31 (10): 520-528 被引量:8
标识
DOI:10.5435/jaaos-d-22-01094
摘要

Introduction: Bone anabolic agents can benefit orthopaedic patients perioperatively and improve outcomes after fragility fractures. However, preliminary animal data raised concern for the potential development of primary bony malignancies after treatment with these medications. Methods: This investigation examined 44,728 patients older than 50 years who were prescribed teriparatide or abaloparatide and compared them with a matched control group to evaluate risk of primary bone cancer development. Patients younger than 50 years with a history of cancer or other risk factors of bony malignancy were excluded. A separate cohort of 1,241 patients prescribed an anabolic agent with risk factors of primary bone malignancy, along with 6,199 matched control subjects, was created to evaluate the effect of anabolic agents. Cumulative incidence and incidence rate per 100,000 person-years were calculated as were risk ratios and incidence rate ratios. Results: The overall risk of primary bone malignancy development for risk factor–excluded patients in the anabolic agent-exposed group was 0.02%, compared with 0.05% in the nonexposed group. The incidence rate per 100,000 person-years was calculated at 3.61 for the anabolic-exposed patients and 6.46 for control subjects. A risk ratio of 0.47 ( P = 0.03) and incidence rate ratio of 0.56 ( P = 0.052) were observed for the development of primary bone malignancies in patients undergoing treatment with bone anabolic agents. Among high-risk patients, 5.96% of the anabolic-exposed cohort developed primary bone malignancies and 8.13% of nonexposed patients developed primary bone malignancy. The risk ratio was 0.73 ( P = 0.01), and the incidence rate ratio was 0.95 ( P = 0.67). Conclusion: Teriparatide and abaloparatide can safely be used for osteoporosis and orthopaedic perioperative management without increased risk of development of primary bone malignancy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
芹菜完成签到,获得积分10
4秒前
热心十八完成签到,获得积分10
4秒前
小兔叽完成签到 ,获得积分10
8秒前
Allen完成签到,获得积分10
9秒前
force完成签到 ,获得积分10
9秒前
asdasdf完成签到,获得积分10
10秒前
chic完成签到 ,获得积分10
10秒前
红颜如梦完成签到 ,获得积分10
10秒前
闪闪慕蕊完成签到 ,获得积分10
11秒前
熙可檬完成签到 ,获得积分10
11秒前
充电宝的应助被ping采纳,获得10
11秒前
wawaeryu完成签到,获得积分10
12秒前
hjj完成签到 ,获得积分10
14秒前
余闻问完成签到,获得积分10
15秒前
15秒前
san完成签到,获得积分10
16秒前
Health完成签到 ,获得积分10
18秒前
2520完成签到 ,获得积分10
19秒前
MJMO完成签到,获得积分10
19秒前
相宜完成签到,获得积分10
20秒前
墨玖辰完成签到,获得积分10
21秒前
高高的哈密瓜完成签到 ,获得积分10
22秒前
阿臭der完成签到 ,获得积分10
22秒前
搬砖的化学男完成签到 ,获得积分10
22秒前
sun完成签到,获得积分10
23秒前
zhouyms完成签到,获得积分10
25秒前
神通广大的MOMO完成签到,获得积分10
26秒前
美满的机器猫完成签到,获得积分10
29秒前
31秒前
Gabi完成签到,获得积分10
31秒前
35秒前
WWW完成签到 ,获得积分10
35秒前
waldoe完成签到,获得积分10
35秒前
36秒前
Laser_eyes完成签到,获得积分10
36秒前
大胆的弼完成签到,获得积分10
36秒前
37秒前
GGG完成签到 ,获得积分10
37秒前
朴素傲松完成签到,获得积分10
37秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185537
求助须知:如何正确求助?哪些是违规求助? 9574270
关于积分的说明 21834871
捐赠科研通 7783247
什么是DOI,文献DOI怎么找? 3434577
关于科研通互助平台的介绍 2558951
邀请新用户注册赠送积分活动 2481370